Outcome in clients with positive pregnancy test following IVF/ICSI treatment
AbstractBackground: A retrospective analysis of the outcome of all patients who have recorded a positive pregnancy test following IVF/ICSI treatment from June 1999 to December 2002 was done.
Materials and Methods: A total of 1256 treatment cycles were carried out using the long day 1 (early follicular phase) or day 21 (mid-luteal phase) protocol using gonadotrophins Menogon, Pergonal or Metrodin 150 300 IU for 12 to 15 days after pituitary down regulation with the GnRH analogue Buserelin.
Results: A total of 258 (20.5%) biochemical pregnancies were recorded. Sixty-seven (26%) resulted in early pregnancy loss (EPL) of which 10 (3.4%) were ectopic pregnancies. Clinical pregnancy occurred in the remaining 191 (74%) patients, with 20 (10.5%) resulting in miscarriages. A total of 160 bab1es (singletons/multiples) had been born by the end of the year 2002 with 40 ongoing pregnancies as at then.
Conclusion: Rate of early pregnancy loss in IVF/ICSI is not higher than in natural cycles and once clinical pregnancy is diagnosed, there is approximately a 90% chance of the pregnancy resulting in live birth, barring obstetric complications.
KeyWords: in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), outcome
Tropical Journal of Obstetrics and Gynaecology Vol. 22(1) 2005: 9-11
The entire contents of the Tropical Journal of Obstetrics and Gynaecology are protected under Indian and international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use.
This journal content is distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.